By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Teva Branded Pharmaceutical
Products R&D Inc. et al. v. Perrigo Pharmaceuticals Co. et al.
1:12-cv-01101; filed September
5, 2012 in the District Court of Delaware

• Plaintiffs:  Teva Branded
Pharmaceutical Products R&D Inc.; Teva Respiratory LLC; Norton (Waterford) Ltd.; Norton Healthcare Ltd.
• Defendants:  Perrigo
Pharmaceuticals Co.; Perrigo Co.; Catalent Pharma Solutions LLC

Infringement of U.S. Patent
Nos. 7,566,445 ("Medicinal Aerosols and Methods of Delivery Thereof,"
issued July 28, 2009) and 7,105,152 ("Suspension Aerosol Formulations,"
issued September 12, 2006) following a Paragraph IV certification as part of
Perrigo's filing of an ANDA to manufacture a generic version of Teva's ProAir®
HFA Inhalation Aerosol (albuterol sulfate, used for the treatment or prevention
of bronchospasm with reversible obstructive airway disease in patients 4 years
of age and older and for the prevention of exercise-induced bronchospasm in
patients 4 years of age and older).  View
the complaint here.

Medicis Pharmaceutical
Corp. v. Actavis Mid Atlantic LLC
1:12-cv-01091; filed August
31, 2012 in the District Court of Delaware

Infringement of U.S. Patent
No. 8,236,816 ("2x2x2 Week Dosing Regimen for Treating Actinic Keratosis
with Pharmaceutical Compositions Formulated with 3.75% Imiquimod," issued
August 7, 2012) following a Paragraph IV certification as part of Actavis'
filing of an ANDA to manufacture a generic version of Medicis' Zyclara® Cream
(3.75% imiquimod cream, used for the topical treatment of clinically typical,
visible, or palpable actinic keratoses ("AK") of the full face or
balding scalp in immunocompetent adults). 
View the complaint here.